Finnish Biosimilar Substitution Proposals Get Pushback From Industry
Local Association Urges Government To Take A More Gradual Approach
Executive Summary
Finnish government proposals to introduce pharmacy-level substitution for biosimilars have been criticized by the country’s generics and biosimilars industry association.
You may also be interested in...
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the most noteworthy and anticipated events for April 2024.
EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.
R&D Industry Finds Biosimilar Interchangeability Statement By EU Regulators ‘Concerning’
A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.